COMP <GO>
MDGL vs TGTX // REVENUE GROWTH (YOY)
Madrigal Pharmaceuticals Inc. (NASDAQ) VS. TG Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: MDGL 3
— TGTX 7
▲ REVENUE GROWTH (YOY) LEADER: MDGL
LAST: $431.16 (+0.19%) • MKT CAP: $9.96B
revenue-growth
180.00%
LAST: $59.95 (-2.01%) • MKT CAP: $9.18B
revenue-growth
87.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDGL VS. TGTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDGL | TGTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.70% | 12.00% | -41.70 | TGTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 73.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.91% | -0.28% | -1.63 | TGTX | /fcf-yield <GO> |
| Operating Margin | -31.30% | 20.00% | -51.30 | TGTX | /operating-margins <GO> |
| Net Profit Margin | -30.10% | 68.00% | -98.10 | TGTX | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 180.00% | 87.30% | +92.70 | MDGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.65 | 12.92 | -5.27 | TGTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 6/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.8 | 60.3 | -29.50 | TGTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.87 | +0.21 | MDGL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 16.7x | +7.30 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.96B | $9.18B | $785.0M | MDGL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDGL REV | TGTX REV | MDGL GROSS % | TGTX GROSS % | MDGL FCF | TGTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $958.4M | $616.3M | — | 83.7% | -$190.0M | -$25.0M |
| FY 2024 | $180.1M | $329.0M | 96.5% | 88.3% | -$457.0M | -$40.6M |
| FY 2023 | $1.07B | $233.7M | — | — | -$324.2M | -$41.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDGL // BETA 1.08
TGTX // BETA 0.87